BLU-701 for Protein Kinase Inhibitors
This trial is testing a new drug, BLU-701, to see if it is safe and effective against EGFRm NSCLC.
- Epidermal Growth Factor Receptor Mutations
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitor Resistance
- Epidermal Growth Factor Receptor Deletion
- Lung Cancer
- Lung Disease
- Bronchial Tumors
- Epidermal Growth Factor Receptor
- Non-Small Cell Lung Cancer
- Respiratory Diseases
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the primary goal of this research endeavor?
"The primary aim of this clinical study, which will last up to two and a half years, is to determine the Maximum Tolerated Dose (MTD) of BLU-701 given as monotherapy or in combination with osimertinib or platinum-based chemotherapy. The secondary aims include assessing Overall Survival (OS), Clinical Benefit Rate (CBR) and treatment-triggered modulation of epidermal growth factor receptor pathway biomarkers such as dual specificity phosphatase 6 (DUSP6) and spouty RTK signaling antagonist 4 (SPRY4)."
Is this experimental protocol still recruiting participants?
"The clinicaltrial.gov portal confirms that this medical trial is actively enrolling patients, with the initial posting having been made on January 13th 2022 and a recent update occurring on June 23rd 2022."
What is the geographical scope of this experiment?
"Eligible participants can be recruited from several hospitals including Henry Ford Hospital in Detroit, Memorial Sloan Kettering Cancer Center in New York and Sarah Cannon Research Institute in Nashville. Additionally, there are 7 other sites available to enrollees."
What is the capacity of participants for this research endeavor?
"Affirmative. As per the details present on clinicaltrials.gov, this investigation is searching for new participants - it was first listed on January 13th 2022 and edited most recently on June 23rd of the same year. 160 volunteers need to be recruited from 7 different research centres."
What other experiments have been executed with BLU-701 as the focus?
"BLU-701 has been the subject of 1070 studies since its inception in 2002 at H Central de Asturias. At present, 850 trials are ongoing with a number of them being conducted out of Detroit, Michigan."